Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$71.63-9.58%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
QuarterlyIQ Insights · CORT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 5.1% |
| Our one-year growth estimate | diamond | 68.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 63.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 1 industry peers · Company calendar date is not available
CORT — CEO transition
Dated 2026-09-23
President — Sean Maduck: The President of the company resigned, representing the loss of a senior executive, although the transition appears orderly with a consulting agreement in place.
Why it matters: This trial tests Lifyorli with two other cancer drugs in ovarian cancer. Positive results could support use beyond the approved treatment.
Watch forBELLA Part A reports results by year-end 2026 that meet its stated trial goals.
Also watch forBELLA Part A misses its stated trial goals or results are not reported by year-end 2026.
Why it matters: Revenue rose to $256.1 million in Q2, and Corcept raised its full-year guide. Results below the guide would weaken that growth signal.
Supportive ifReported 2026 revenue lands within or above the $1.1-$1.2 billion range.
Worry ifCorcept cuts its 2026 revenue guide below $1.1 billion or reports full-year revenue below that level.
Why it matters: MONARCH tests miricorilant in people with MASH. A clear benefit would add evidence for a new use; a failed trial would weaken this program.
Watch forMONARCH reports results by year-end 2026 and meets its main trial goal.
Also watch forMONARCH misses its main trial goal or results are not reported by year-end 2026.
Why it matters: Lifyorli is a new source of sales. More patients and rising sales would show that the launch is gaining ground.
Supportive ifA later quarter reports Lifyorli sales above $47.6 million. More than 1,300 patients were treated.
Worry ifA later quarter reports Lifyorli sales at or below $47.6 million, with no rise in treated patients.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$181 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $486 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,346 loss on $10,000 · 63.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.